New drug tested for Tough-to-Treat blood cancers
NCT ID NCT05627856
Summary
This early-stage study is testing an experimental drug called GNC-038 in adults with specific types of lymphoma that have returned or not responded to standard treatments. The main goals are to find a safe and tolerable dose and to see if the drug can shrink tumors. The study will also measure how the drug moves through the body and how the immune system reacts to it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510120, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China
Conditions
Explore the condition pages connected to this study.